A RetroSearch Logo

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Search Query:

Showing content from https://pubmed.ncbi.nlm.nih.gov/27601354/ below:

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

Randomized Controlled Trial

doi: 10.2196/jmir.6414. A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

Affiliations

Affiliation

Item in Clipboard

Randomized Controlled Trial

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

Marco Egbring et al. J Med Internet Res. 2016.

Affiliation

Item in Clipboard

Abstract

Background: The well-being of breast cancer patients and reporting of adverse events require close monitoring. Mobile apps allow continuous recording of disease- and medication-related symptoms in patients undergoing chemotherapy.

Objective: The aim of the study was to evaluate the effects of a mobile app on patient-reported daily functional activity in a supervised and unsupervised setting.

Methods: We conducted a randomized controlled study of 139 breast cancer patients undergoing chemotherapy. Patient status was self-measured using Eastern Cooperative Oncology Group scoring and Common Terminology Criteria for Adverse Events. Participants were randomly assigned to a control group, an unsupervised group that used a mobile app to record data, or a supervised group that used the app and reviewed data with a physician. Primary outcome variables were change in daily functional activity and symptoms over three outpatient visits.

Results: Functional activity scores declined in all groups from the first to second visit. However, from the second to third visit, only the supervised group improved, whereas the others continued to decline. Overall, the supervised group showed no significant difference from the first (median 90.85, IQR 30.67) to third visit (median 84.76, IQR 18.29, P=.72). Both app-using groups reported more distinct adverse events in the app than in the questionnaire (supervised: n=1033 vs n=656; unsupervised: n=852 vs n=823), although the unsupervised group reported more symptoms overall (n=4808) in the app than the supervised group (n=4463).

Conclusions: The mobile app was associated with stabilized daily functional activity when used under collaborative review. App-using participants could more frequently report adverse events, and those under supervision made fewer and more precise entries than unsupervised participants. Our findings suggest that patient well-being and awareness of chemotherapy adverse effects can be improved by using a mobile app in collaboration with the treating physician.

Clinicaltrial: ClinicalTrials.gov NCT02004496; https://clinicaltrials.gov/ct2/show/NCT02004496 (Archived by WebCite at http://www.webcitation.org/6k68FZHo2).

Keywords: breast cancer; breast neoplasms; collaboration; daily functional activity; mobile app.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1

CONSORT diagram demonstrating the flow…

Figure 1

CONSORT diagram demonstrating the flow of patients.

Figure 1

CONSORT diagram demonstrating the flow of patients.

Figure 2

Visual analog scale for current…

Figure 2

Visual analog scale for current and worst daily functional activity in the questionnaire.

Figure 2

Visual analog scale for current and worst daily functional activity in the questionnaire.

Figure 3

Participants who used the Internet…

Figure 3

Participants who used the Internet to obtain disease-specific information.

Figure 3

Participants who used the Internet to obtain disease-specific information.

Similar articles Cited by References
    1. Cordova FC, Ciccolella D, Grabianowski C, Gaughan J, Brennan K, Goldstein F, Jacobs MR, Criner GJ. A telemedicine-based intervention reduces the frequency and severity of COPD exacerbation symptoms: a randomized, controlled trial. Telemed J E Health. 2015 Aug 10;:e1. doi: 10.1089/tmj.2015.0035. - DOI - PMC - PubMed
    1. Breen S, Ritchie D, Schofield P, Hsueh Y, Gough K, Santamaria N, Kamateros R, Maguire R, Kearney N, Aranda S. The Patient Remote Intervention and Symptom Management System (PRISMS): a Telehealth-mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial. Trials. 2015;16:472. doi: 10.1186/s13063-015-0970-0. http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0970-0 - DOI - DOI - PMC - PubMed
    1. Wong S, Bounthavong M, Nguyen CP, Chen T. Outcome assessments and cost avoidance of an oral chemotherapy management clinic. J Natl Compr Canc Netw. 2016 Mar;14(3):279–285. - PubMed
    1. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001 Jun 28;344(26):1997–2008. doi: 10.1056/NEJM200106283442607. - DOI - PubMed
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3